title: FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.
abstract: Genetic or epigenetic inactivation of the pathway formed by the Fanconi Anemia (FA) and BRCA proteins occurs in several cancer types, including lung and breast cancer, rendering the affected tumors potentially hypersensitive to DNA crosslinking agents. However, the cytotoxicity of other commonly used cancer therapeutics in cells with FA/BRCA pathway defects remains to be defined. Building on earlier data that implicated BRCA1 and BRCA2 in the repair of DNA damage caused by the topoisomerase II poison etoposide, we studied the role of FANCD2 in mediating resistance to several topoisomerase II poisons. We establish that the loss of FANCD2 increases cell death in response to etoposide. FANCD2 promotes homologous recombination repair (HRR) and prevents DNA double-strand break formation and chromosomal aberrations in etoposide-treated cells. Strikingly, this function of FANCD2 is independent of FANCD2 foci formation and of FANCA, which is a member of the FA core complex upstream of FANCD2 mono-ubiquitination. Thus, FANCD2 appears to promote HRR in a mono-ubiquitination-independent manner in conjunction with BRCA1/2. These data add to an emerging body of evidence indicating that the FA pathway is not linear and that several protein subcomplexes with different functions exist. Our findings are potentially relevant for predicting the sensitivity of lung and breast cancers to etoposide and doxorubicin, respectively.
authors.affiliation: Laboratory of Cellular & Molecular Radiation Oncology, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Kachnic
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Loreen
authors.initials: L
authors.lastname: Fournier
authors.forename: Natalie
authors.initials: N
authors.lastname: Ferraiolo
authors.forename: Jochen
authors.initials: J
authors.lastname: Dahm-Daphi
authors.forename: Kerstin
authors.initials: K
authors.lastname: Borgmann
authors.forename: Henning
authors.initials: H
authors.lastname: Willers
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002460:Cell Line; D053903:DNA Breaks, Double-Stranded / Q000187:drug effects; D004260:DNA Repair / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D005047:Etoposide / Q000494:pharmacology*; D052217:Fanconi Anemia Complementation Group A Protein / Q000378:metabolism*; D052236:Fanconi Anemia Complementation Group D2 Protein / Q000378:metabolism*; D005455:Fluorescent Antibody Technique; D006801:Humans; D034622:RNA Interference; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology; D059005:Topoisomerase II Inhibitors / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; C498471:FANCA protein, human; C499905:FANCD2 protein, human; D052217:Fanconi Anemia Complementation Group A Protein; D052236:Fanconi Anemia Complementation Group D2 Protein; D059005:Topoisomerase II Inhibitors; D005047:Etoposide; D004250:DNA Topoisomerases, Type II